Fig. 3

Regional disparities in treatment outcome in patients with chronic hepatitis C treated by peginterferon-α and ribavirin (P/R). In the entire P/R-treated cohort (n = 14,061), the treatment outcome was as follows: the rates of sustained virological response (SVR), transient virological response (TVR), non-virological response (NVR), and undetermined response were 56.7 %, 20.6 %, 18.6 %, and 4.1 %, respectively. There were regional disparities among the nine regions in treatment outcome (P < 0.001)